Intellia Therapeutics (NTLA) Q3 2024 earnings summary

Executive summary

• Achieved significant clinical progress in CRISPR-based gene editing, with positive Phase 2 results for NTLA-2002 in hereditary angioedema (HAE) and rapid advancement of late-stage trials for ATTR amyloidosis and alpha-1 antitrypsin deficiency (AATD).

• FDA cleared IND for MAGNITUDE-2 Phase 3 trial in ATTR amyloidosis with polyneuropathy; three Phase 3 studies expected by year-end.

• Strong patient and investigator enthusiasm is driving rapid enrollment in pivotal studies, with MAGNITUDE and HAELO Phase 3 trials enrolling ahead of projections.

• Lead in vivo candidates include NTLA-2001 for ATTR amyloidosis, NTLA-2002 for HAE, and NTLA-3001 for AATD, with NTLA-3001 entering first-in-human studies.

• Collaboration revenue is the sole source of revenue to date, with major partners including Regeneron, Sparing Vision, AvenCell, Kyverna, and ReCode.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $944.7 million as of September 30, 2024, down from $1 billion at year-end 2023.

• Collaboration revenue was $9.1 million in Q3 2024, compared to $12 million in Q3 2023, mainly due to reduced AvenCell license revenue.

• R&D expenses rose to $123.4 million in Q3 2024 from $113.7 million in Q3 2023, driven by advancement of lead programs.

• G&A expenses increased to $30.5 million in Q3 2024 from $29.4 million in Q3 2023, primarily due to stock-based compensation.

• Net loss for Q3 2024 was $135.7 million ($1.34/share), compared to $122.2 million ($1.38/share) in Q3 2023.

Outlook and guidance

• Cash position expected to fund operations into late 2026, excluding potential milestone payments.

• BLA submission for NTLA-2002 in HAE planned for 2026, with Phase 3 HALO/HAELO study enrolling rapidly.

• MAGNITUDE-2 Phase 3 trial in ATTR polyneuropathy to initiate ex-U.S. shortly; primary endpoint at 18 months.

• First patient dosing for NTLA-3001 in AATD expected by year-end; data possible in 2025.

• Expenses are expected to increase as clinical programs advance and new programs enter development.